Objective: To evaluate if remission induced by low-dose prednisolone during the first 2 years of rheumatoid arthritis (RA) in the BARFOT glucocorticoid (GC) study had sustained effect on radiological damage for a total of 4 years.
Methods: A total of 150 of 211 eligible RA patients who had been randomized to 7.5 mg prednisolone (P-group) or no prednisolone (NoP-group) in addition to the initial disease-modifying drug (DMARD) were included. Radiographs of hands and feet were scored using the Sharp van der Heijde scoring method. Remission was defined as DAS28 below 2.6.
Results: Mean(SD) age was 53(14) and 57(12) years for the P and NoP patients, respectively. 64% were female, 64% RF positive and disease duration at baseline was 6 months. At 2 years the proportion of patients in remission in the P and NoP groups was 55 vs 30%, p=0.003. Longitudinal analysis showed that over the entire course of the disease, patients on prednisolone had a higher probability of being in remission. Patients in remission at 2 years had, compared with those not in remission, significantly lower total Sharp score, erosion score and joint space narrowing score at 2 and 4 years. The changes in bone mineral density during the four years did not differ between those in remission and those not and were similar in the two treatment groups.
Conclusion: Prednisolone 7.5 mg daily in addition to DMARD increases the rate of remission in patients with early RA, which has a beneficial and sustained effect on radiological damage.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.